We are currently working to resolve technical issues preventing us from processing applications or payment for membership. Please email Membership on subscriptions@rheumatology.org.uk with any queries.

Our Standards, Audit and Guidelines Working Group (SAGWG) has opened a call for topic suggestions for future evidence-based guidelines.


Professionals from any clinical discipline in the UK rheumatology community are welcome to submit their ideas by Wednesday 31 August. All proposals will be reviewed at SAGWG's October meeting.

BSR’s guideline development process has been accredited by NICE and guideline users can be confident of the quality of the final recommendations. Each topic proposal should:


  • Provide a short title and the specific objective(s) for the proposed guideline
  • Provide an overview (<2 pages) of the topic that highlights relevant background information (with key supporting references)
  • Explain the burden/importance of the condition/health care intervention. SAGWG will want to gauge if it is large enough to warrant guideline development. If you can, provide some estimate of the burden (e.g., incidence, prevalence, costs). 
  • Explain if there is uncertainty or controversy about the relative effectiveness of the available clinical strategies for the condition(s) for which a guideline is proposed. If you can, provide some examples/assessment of this uncertainty. 
  • Describe perceived or documented variation in practice in the management of a given condition or use of a particular healthcare intervention. Provide some  assessment/references related to significant differences in practice patterns
  • Show if there sufficient scientific evidence of good quality to allow development of a guideline. Provide some references, particularly randomised controlled studies to  support the development of systematic reviews and analysis of the topic
  • State if there are existing guidelines on the proposed topic. If a guideline was to be developed and we assume appropriate dissemination, can you argue that it would make a significant impact on clinical decision-making/clinical outcomes and/or reduce practice variation?

Submit proposal

[Questions 1-7 reprinted/adapted with permission ©2013. American Society of Clinical Oncology. All rights reserved]